OXACILLIN- oxacillin sodium injection, powder, for solution Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

oxacillin- oxacillin sodium injection, powder, for solution

renaissance ssa, llc - oxacillin sodium (unii: g0v6c994q5) (oxacillin - unii:uh95vd7v76) - oxacillin 1 g in 1 g - oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug.  (see  clinical pharmacology: susceptibility testing ) oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. oxacillin should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with oxacillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of oxacillin for injection, usp and other antibacterial drugs, oxacillin for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected

PREPOPIK- sodium picosulfate, magnesium oxide, and anhydrous citric acid powder, metered Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

prepopik- sodium picosulfate, magnesium oxide, and anhydrous citric acid powder, metered

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

FEXMID cyclobenzaprine hydrochloride tablet film coated Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

fexmid cyclobenzaprine hydrochloride tablet film coated

shionogi inc. - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine hydrochloride 7.5 mg

HUMAN PARVOVIRUS HOMOCHORD- parvovirus nosode liquid Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

human parvovirus homochord- parvovirus nosode liquid

deseret biologicals, inc. - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

HUMAN PARVOVIRUS REMEDY- parvovirus nosode (b19) liquid Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

human parvovirus remedy- parvovirus nosode (b19) liquid

deseret biologicals, inc - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml - for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

HUMAN PARVOVIRUS REMEDY- parvovirus liquid Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

human parvovirus remedy- parvovirus liquid

apotheca company - human parvovirus b19 (unii: 94n635564t) (human parvovirus b19 - unii:94n635564t) - human parvovirus b19 15 [hp_x] in 1 ml -     indications:  for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever. indications:   for the temporary relief of symptoms related to parvovirus including rash, swollen, painful joints and fever.

Sodium Chloride 0.3 % w/v and Glucose 3.3% w/v Solution for Infusion BP Irska - engleski - HPRA (Health Products Regulatory Authority)

sodium chloride 0.3 % w/v and glucose 3.3% w/v solution for infusion bp

baxter holding b.v. - sodium chloride; glucose - solution for infusion - 0.3/ 3.3 percent weight/volume - salt solutions; sodium chloride

Sodium Chloride 0.45 % w/v and Glucose 2.5% w/v Solution for Infusion BP Irska - engleski - HPRA (Health Products Regulatory Authority)

sodium chloride 0.45 % w/v and glucose 2.5% w/v solution for infusion bp

baxter holding b.v. - sodium chloride; glucose - solution for infusion - 0.45/2.5 percent weight/volume - salt solutions; sodium chloride

Sodium Chloride 0.9 % w/v and Glucose 5% w/v Solution for Infusion BP (Viaflo container) Irska - engleski - HPRA (Health Products Regulatory Authority)

sodium chloride 0.9 % w/v and glucose 5% w/v solution for infusion bp (viaflo container)

baxter holding b.v. - sodium chloride; glucose - solution for infusion - 0.9/5 percent weight/volume - salt solutions; sodium chloride

BIOLOGICAL THERAPIES DISODIUM EDETATE SOLUTION 3g/100mL injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

biological therapies disodium edetate solution 3g/100ml injection vial

orthomolecular medisearch laboratories pty ltd trading as biological therapies - disodium edetate, quantity: 30 mg/ml - injection, concentrated - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, cons